ribavirin
either
free
aqueou
solut
incorpor
liposom
evalu
specificpathogenfre
kitten
experiment
challeng
exposur
felin
infecti
periton
viru
fipv
ribavirin
administ
daili
day
mg
kg
bodyweight
given
per
os
intramuscularli
intraven
begin
hour
kitten
challengeexpos
fipv
kitten
includ
ribavirintr
untreat
kitten
succumb
fip
clinic
sign
diseas
sever
ribavirintr
kitten
mean
surviv
time
shorten
clinic
efficaci
free
ribavirin
given
intraven
reduc
dosag
mg
kg
bodyweight
compar
ribavirin
incorpor
lecithincontain
liposom
mg
kg
intraven
drug
given
daili
three
consecut
day
week
three
week
begin
hour
viru
challeng
exposur
signific
differ
either
surviv
rate
sever
diseas
kitten
given
free
ribavirin
liposom
ribavirin
salin
intrins
toxic
low
therapeut
index
fipv
margin
antivir
activ
vivo
maxim
dose
ribavirin
present
recommend
primari
antivir
chemotherapi
fip
felin
infecti
periton
fip
fatal
immunemedi
diseas
cat
caus
coronaviru
fipv
weiss
fipv
replic
within
dissemin
system
monocyt
macrophag
particularli
blood
liver
spleen
lymph
node
lung
bone
marrow
mesothelium
ward
weiss
scott
b
weiss
effect
immunis
fp
report
recent
report
gerber
et
al
vaccin
consist
attenu
temperaturesensit
mutant
strain
fipv
efficaci
protect
kitten
experiment
challeng
expos
fnv
howev
still
effect
therapi
fip
although
immunosuppress
drug
induc
temporari
clinic
remiss
diseas
consid
gener
untreat
pedersen
pedersen
vitro
antivir
studi
indic
fipv
suscept
human
felin
interferon
toiviokinnucan
weiss
oostromram
ribavirin
oostromram
barlough
scott
adenin
arabinosid
amphotericin
b
barlough
scott
ribavirin
carboxamid
nucleosid
analogu
guanosin
broad
spectrum
virostat
activ
variou
rna
dna
virus
nicholson
rein
gross
vitro
cytotox
studi
ribavirin
suggest
potenti
toxic
antivir
dosag
cat
oostromram
weiss
vivo
drug
moder
toxic
dosag
mg
kg
bodyweight
variou
rout
healthi
cat
weiss
et
al
experiment
trial
interferon
cat
inocul
fipv
gener
disappoint
weiss
weiss
et
al
novel
mean
deliv
small
therapeut
dosag
drug
first
microencapsul
liposom
inocul
liposom
intraven
alv
macewen
kend
et
al
liposom
biodegrad
unilamellar
multilamellar
phospholipid
vesicl
similar
structur
plasma
membran
mark
affin
intraven
administr
reticuloendotheli
cell
predominantli
macrophag
liver
lung
spleen
alv
macewen
liposom
use
deliv
chemotherapeut
agent
macrophag
anim
infect
virus
bacteria
fungi
protozoa
kend
et
al
experiment
infect
murin
leishmaniasi
liposomeencapsul
drug
time
effect
nonencapsul
drug
form
treatment
kend
et
al
administr
liposomeencapsul
ribavirin
mice
infect
rift
valley
fever
viru
result
liver
ribavirin
concentr
fivefold
greater
attain
dose
free
ribavirin
mice
challeng
expos
lethal
amount
viru
moreov
protect
diseas
wherea
treat
dose
free
drug
succumb
lethal
infect
kend
et
al
consid
vivo
efficaci
vitro
toxic
ribavirin
also
decid
investig
use
liposom
mean
encapsul
deliv
ribavirin
could
advantag
lower
requir
therapeut
dose
toxic
drug
might
target
specif
macrophag
variou
reticuloendotheli
organ
target
tissu
fipv
previou
toxic
studi
ribavirin
author
laboratori
indic
clinic
toxic
occur
dosag
mg
kg
weiss
et
al
investig
observ
ribavirin
administ
intramuscularli
empir
dosag
approxim
mg
kg
bodyweight
well
toler
sever
week
cat
infect
upper
respiratori
tract
virus
dr
e
colbi
dartmouth
univers
medic
school
person
commun
initi
studi
perform
report
trial
evalu
efficaci
free
ribavirin
experiment
induc
fip
drug
use
dosag
mg
kg
bodyweight
author
believ
dosag
would
still
safe
given
variou
rout
incorpor
liposom
object
studi
report
evalu
ribavirin
administ
either
alon
maxim
toler
dose
incorpor
liposom
similar
dose
antivir
treatment
fip
fifti
healthi
specificpathogenfre
kitten
either
sex
obtain
commerci
breed
coloni
liberti
laboratori
kitten
felvantigenneg
elisa
seroneg
felin
coronaviru
felin
immunodefici
viru
antibodi
kitten
hous
individu
feder
approv
stainless
steel
cage
temperatur
light
humidityregul
isol
room
scottritchey
anim
isol
facil
colleg
veterinari
medicin
auburn
univers
alabama
food
water
provid
ad
libiturn
litter
pan
chang
daili
anim
use
maintain
accord
us
feder
guidelin
experiment
protocol
approv
auburn
univers
institut
anim
care
use
committe
strain
fpv
atcc
use
inocul
experiment
anim
detect
fipvneutralis
antibodi
titr
fipv
approxim
tissu
cultur
infect
dose
titrat
determin
inoculum
contain
cat
lethal
dose
crandel
felin
kidney
crfk
cell
propag
eagl
minimum
essenti
medium
supplement
per
cent
heatinactiv
fetal
bovin
serum
iu
penicillin
gg
streptomycin
tg
amphotericin
along
mm
lglutamin
per
cent
nonessenti
amino
acid
cultur
maintain
humidifi
incub
atmospher
air
per
cent
carbon
dioxid
ribavirin
lot
number
virazol
suppli
dr
hine
solvay
anim
health
mendota
height
minnesota
store
lyophilis
room
temperatur
dilut
use
aqueou
solut
ribavirin
made
mix
lyophilis
powder
phosphat
buffer
salin
solut
pbss
ph
filter
solut
gm
cellulos
acet
filter
come
ribavirin
solut
store
maximum
hour
use
vitro
screen
aliquot
ribavirin
use
previous
describ
procedur
weiss
oostromram
confirm
antivir
activ
fipv
gener
lecithin
obtain
commerci
manufactur
lot
number
powder
lecithin
suppli
dr
j
gerber
smithklin
beecham
anim
health
lincoln
nebraska
lecithin
suppli
dri
granul
powder
autoclav
lb
pressur
minut
store
room
temperatur
use
suspens
empti
liposom
liposomeencapsul
ribavirin
made
reconstitut
dri
phospholipidcontain
lecithin
granul
pbss
pbss
contain
steril
ribavirin
final
concentr
mg
solut
agit
minut
mixtur
form
homogen
creamybrown
consist
phasecontrast
microscopi
liposom
prepar
reveal
mixtur
predominantli
per
cent
small
unilamellar
vesicl
gm
diamet
along
occasion
larg
multilamellar
onionshap
vesicl
approxim
tm
size
calcul
lipid
drug
ratio
liposomeencapsul
ribavirin
suspens
per
cent
wv
liposom
store
maximum
period
five
day
use
data
manufactur
indic
similarli
prepar
liposom
contain
variou
compound
stabl
sever
week
smithklin
beecham
anim
health
product
unpublish
data
percentag
entrap
ribavirin
liposom
determin
lyse
liposom
deterg
extract
releas
ribavirin
aqueou
phase
chloroformalcohol
gradient
calcul
concentr
extract
ribavirin
spectrophotometr
use
standard
curv
briefli
liposom
mix
ribavirin
predetermin
concentr
wash
pbss
ultracentrifug
g
remov
unincorpor
ribavirin
pellet
resuspend
pbss
liposom
vesicl
lyse
ad
per
cent
vv
triton
r
c
weiss
n
r
cox
l
martinez
sigma
sampl
detergenttr
liposom
visualis
phasecontrast
microscopi
confirm
vesicl
ruptur
intraliposom
ribavirin
isol
aqueou
pbss
phase
four
success
extract
chloroformisoamyl
alcohol
intraliposom
ribavirin
concentr
determin
spectrophotometr
absorb
nm
maximum
ultraviolet
absorb
peak
ribavirin
pbss
extrapol
standard
curv
known
ribavirin
concentr
encapsul
effici
ee
liposom
ribavirin
express
percentag
origin
drugload
dose
per
cent
valu
calcul
accord
follow
equat
ribavirin
wash
lyse
liposom
ee
x
ribavirin
unwash
intact
liposom
mg
mg
x
x
per
cent
kitten
six
kitten
per
group
use
evalu
efficaci
ribavirin
given
variou
rout
mg
kg
bodyweight
antivir
treatment
fn
day
inocul
kitten
sedat
use
combin
telazol
zolazepam
hydrochlorid
mg
kg
bodyweight
intramuscularli
ah
robbin
atropin
sulphat
mg
kg
bodyweight
subcutan
blood
collect
jugular
venepunctur
vacuumevacu
glass
tube
without
anticoagul
determin
fipv
neutralis
antibodi
vna
serum
kitten
inocul
intraperiton
approxim
fpv
eighteen
hour
vipv
inocul
day
kitten
given
ribavirin
per
os
intramuscularli
intraven
given
solut
pbss
intraven
drug
pbss
administ
kitten
daili
next
day
nine
day
intraven
ribavirin
salinetr
group
kitten
examin
daili
weigh
twice
weekli
adjust
drug
amount
weight
chang
clinic
score
correl
invers
health
anim
calcul
daili
kitten
basi
numer
scale
reflect
sever
clinic
sign
ribavirin
felin
infecti
periton
follow
anorexia
depress
fever
ocular
nasal
discharg
fever
dehydr
weight
loss
baselin
kg
hypothermia
less
pale
mucou
membran
slow
capillari
refil
time
vomit
diarrhoea
andor
melaena
weight
loss
kg
labour
breath
central
nervou
system
sign
seizur
tremor
paralysi
coma
death
day
inocul
kitten
sedat
bled
vna
serum
titr
describ
necropsi
examin
perform
kitten
die
studi
kitten
euthanas
moribund
fip
surviv
kitten
observ
clinic
period
least
nine
month
inocul
fipv
trial
kitten
evalu
twentyfour
kitten
inocul
intranas
oronas
day
total
dose
approxim
fipv
kitten
six
per
group
treat
follow
ribavirin
mg
kg
bodyweight
intraven
ribavirin
incorpor
liposom
mg
kg
bodyweight
intraven
along
small
amount
approxim
mg
kg
bodyweight
intraven
unincorpor
free
ribavirin
empti
liposom
ml
kg
bodyweight
intraven
pbss
viru
control
ml
kg
bodyweight
intraven
treatment
given
daili
three
consecut
day
week
three
week
start
hour
fipv
challengeexposur
day
two
kitten
inject
similarli
empti
liposom
ml
kg
bodyweight
intraven
challeng
expos
fipv
liposom
toxic
control
kitten
euthanas
necropsi
day
sampl
collect
clinic
score
necropsi
kitten
trial
perform
describ
kitten
trial
neutralis
antibodi
measur
use
standard
infectivityinhibit
microassay
assay
perform
essenti
describ
weiss
et
al
except
crfk
ceil
use
indic
cell
viral
cytopath
effect
score
hour
kitten
examin
gross
chang
repres
section
organ
macroscop
lesion
fix
per
cent
neutral
buffer
formalin
fix
tissu
embed
paraffin
section
gin
stain
haematoxylin
eosin
h
e
examin
light
microscopi
touch
impress
bone
marrow
kitten
made
glass
slide
airdri
stain
use
modifi
wright
stain
bone
marrow
smear
examin
light
microscopi
evalu
describ
previous
weiss
et
al
analysi
data
perform
use
computeris
statist
analysi
program
abstat
andersonbel
differ
surviv
rate
group
evalu
z
analysi
mean
differ
cumul
surviv
rate
group
trial
test
signific
kurskalw
oneway
analysi
varianc
rank
data
use
nonparametr
method
mean
differ
vna
titr
clinic
score
bodyweight
analys
twotail
student
test
p
valu
less
consid
signific
daili
administr
ribavirin
mg
kg
bodyweight
per
os
intramuscularli
intraven
kitten
day
intraperiton
inocul
lethal
dose
hpv
protect
kitten
fip
mortal
mean
median
surviv
time
actual
decreas
ribavirintr
kitten
challeng
expos
fipv
compar
untreat
control
kitten
p
kitten
given
ribavirin
oral
tabl
predomin
clinic
sign
fever
depress
anorexia
dehydr
weight
loss
icteru
mucou
membran
pallor
hypothermia
termin
stage
diseas
although
fever
first
occur
day
inocul
untreat
kitten
kitten
given
ribavirin
intra
muscularli
fever
delay
hour
three
six
kitten
given
ribavirin
oral
three
five
kitten
given
ribavirin
intraven
mean
clinic
score
increas
significantli
compar
untreat
kitten
ribavirin
treatment
group
day
p
oral
intraven
intramuscularli
treat
kitten
respect
day
oral
p
intraven
p
group
day
intramuscular
group
p
fig
mean
decreas
bodyweight
greater
infect
ribavirintr
kitten
infect
untreat
kitten
day
mean
weight
loss
day
untreat
kitten
ribavirintr
kitten
kitten
fipv
neutralis
antibodi
day
viru
inocul
fig
signific
increas
mean
vna
titr
observ
day
infect
untreat
kitten
compar
kitten
given
ribavirin
either
oral
p
intraven
p
vna
kitten
given
ribavirin
intramuscularli
tend
p
decreas
mean
sem
vna
titr
untreat
kitten
kitten
treat
oral
intramuscularli
intraven
respect
rapid
increas
vna
titr
occur
kitten
day
mean
sem
vna
titr
day
untreat
kitten
one
surviv
kitten
treat
oral
ribavirin
intraven
treat
kitten
intramuscularli
treat
kitten
although
mean
vna
titr
intramuscularli
treat
kitten
less
group
differ
signific
magnitud
vna
titr
correl
posit
clinic
respons
group
induc
experiment
intraperiton
inocul
fipv
contrast
untreat
kitten
howev
kitten
treat
ribavirin
rel
greater
incid
haemorrhag
lesion
involv
intestin
tract
small
larg
bowel
fiftyf
per
cent
six
kitten
given
ribavirin
oral
intramuscularli
cerebr
haemorrhag
contrast
none
infect
kitten
given
ribavirin
intraven
one
infect
untreat
kitten
haemorrhag
brain
kitten
oral
intramuscular
ribavirin
group
greater
number
haemorrhag
lesion
untreat
kitten
given
ribavirin
intraven
kitten
latter
two
group
mild
haemorrhag
confin
mostli
upper
bowel
wherea
kitten
treat
ribavirin
oral
intramuscularli
pronounc
haemorrhag
petechia
diffus
small
larg
intestin
liver
heart
lung
diaphragm
subcutan
tissu
brain
signific
differ
surviv
rate
fipv
challeng
exposur
observ
untreat
kitten
treat
either
free
ribavirin
mg
kg
intraven
ribavirin
treatment
group
receiv
mg
ribavirin
kg
bodyweight
intraven
daili
three
consecut
day
start
week
three
week
begin
hour
viru
exposur
liposom
without
ribavirin
pbss
alon
given
intraven
dosag
ml
kg
bodyweight
kitten
inocul
oronas
frpv
first
day
studi
kitten
die
cardiac
arrest
liposom
administr
second
week
studi
exclud
data
smean
surviv
time
calcul
basi
surviv
week
postinocul
infecti
periton
liposom
mg
kg
intraven
group
kitten
treat
empti
liposom
fewer
survivor
none
six
challengeexposur
fipv
untreat
kitten
two
six
given
free
ribavirin
three
six
liposom
ribavirin
two
five
tabl
differ
howev
signific
x
analysi
median
mean
surviv
time
kitten
receiv
free
ribavirin
greater
surviv
time
untreat
kitten
kitten
given
liposom
ribavirin
empti
liposom
tabl
notabl
increas
surviv
rate
four
week
viru
challeng
exposur
group
kitten
given
free
ribavirin
compar
group
fig
surviv
rate
mean
surviv
time
week
fipv
inocul
per
cent
four
six
kitten
day
kitten
receiv
free
ribavirin
per
cent
two
six
kitten
day
untreat
kitten
per
cent
two
five
kitten
day
kitten
given
liposomeencapsul
ribavirin
per
cent
none
six
kitten
day
kitten
given
empti
liposom
respect
signific
differ
clinic
score
observ
among
group
although
kitten
treat
free
ribavirin
tend
p
lower
score
fewer
clinic
sign
day
untreat
kitten
fig
clinic
sign
fip
similar
describ
kitten
trial
kitten
give
liposomeencapsul
ribavirin
nonsignific
decreas
mean
bodyweight
kg
day
compar
weight
loss
either
untreat
kitten
kg
kitten
given
empti
liposom
kg
kitten
receiv
free
ribavirin
kg
kitten
treat
intraven
liposom
without
ribavirin
frequent
acut
respiratori
distress
includ
dyspnoea
apnoea
treatment
reaction
abat
rate
deliveri
consider
decreas
one
kitten
presed
tiletamin
acut
respiratori
failur
liposom
administr
die
cardiac
arrest
day
necropsi
examin
kitten
reveal
earli
fip
lesion
lung
liver
haemorrhag
haemoperitoneum
two
uninfect
kitten
receiv
equival
dosag
empti
liposom
ml
kg
bodyweight
intraven
remain
healthi
lose
weight
show
sign
diseas
kitten
seroconvert
fipv
day
vna
titr
increas
progress
cours
diseas
fig
although
vna
titr
kitten
given
free
ribavirin
tend
lower
particularli
first
five
week
challeng
exposur
group
signific
differ
magnitud
antibodi
respons
group
observ
kitten
die
kill
lesion
typic
fn
lesion
includ
vascul
perivascul
fibrinonecrotis
pyogranulomat
inflamm
haemorrhag
seros
parenchym
organ
includ
respiratori
tract
kitten
lymph
node
liver
intestin
tract
kidney
spleen
central
nervou
system
fifteen
kitten
haemorrhag
variou
organ
commonli
affect
intestin
tract
kitten
eleven
kitten
thymic
atrophi
nine
kitten
seven
die
day
show
lesion
characterist
effus
form
fn
includ
thorac
abdomin
effus
extent
lesion
vari
markedli
among
individu
kitten
notabl
differ
either
type
sever
lesion
includ
haemorrhag
among
treatment
group
kitten
given
ribavirin
averag
surviv
longer
kitten
tend
slightli
higher
incid
chronic
inflammatori
noneffusivetyp
fip
lesion
examin
bone
marrow
impress
smear
formalinfix
marrow
section
reveal
fipv
challeng
expos
untreat
kitten
increas
bone
marrow
cellular
includ
rel
increas
megakaryocyt
osteoclast
moder
myeloid
left
shift
normal
number
erythroid
precursor
kitten
given
ribavirin
increas
bone
marrow
cellular
slight
myeloid
left
shift
decreas
number
erythroid
precursor
either
normal
decreas
number
megakaryocyt
kitten
given
liposom
ribavirin
increas
bone
marrow
cellular
mark
megakaryocytosi
slight
myeloid
left
shift
wherea
given
empti
liposom
increas
bone
marrow
cellular
erythroid
hypoplasia
erythrophagocytosi
either
increas
decreas
number
megakaryocyt
kitten
given
empti
liposom
challeng
expos
fipv
notabl
chang
bone
marrow
likelihood
drug
toxic
rel
high
dose
ribavirin
cat
infect
fipv
predict
basi
low
therapeut
index
ribavirin
fpvinfect
felin
cell
cultur
weiss
oostromram
base
find
previou
toxicolog
studi
believ
dose
mg
ribavirin
kg
bodyweight
given
alon
variou
rout
kitten
challeng
expos
fipv
would
still
suffici
toler
thu
allow
author
evalu
independ
antivirai
properti
apart
signific
drug
toxic
trial
kitten
treat
daili
day
mg
ribavirin
kg
bodyweight
per
os
intramuscularli
intraven
challeng
exposur
lethal
dose
fipv
trial
howev
protect
virusinduc
diseas
mortal
ribavirintr
kitten
actual
sever
weight
loss
clinic
sign
diseas
decreas
surviv
time
sever
haemorrhag
lesion
fipv
challeng
exposur
untreat
kitten
suggest
clinic
toxic
dosag
despit
increas
sever
clinic
sign
ribavirintr
kitten
delay
onset
fever
viru
inocul
decreas
mean
vna
respons
day
suggest
antivir
activ
ribavirin
vivo
delay
onset
clinic
sign
reduc
vna
titr
ribavirintr
kitten
fipv
challeng
exposur
howev
may
caus
initi
immunosuppress
myelotox
effect
drug
rather
direct
antivir
action
similar
effect
earli
clinic
diseas
antibodi
titr
observ
fipv
experiment
infect
kitten
treat
daili
immunosuppress
dose
infecti
periton
interferono
previou
studi
weiss
et
al
ribavirin
toxic
cat
demonstr
previous
vitro
also
vivo
higher
dosag
report
trial
povey
b
weiss
toviokinnucan
weiss
oostromram
weiss
et
al
toxic
effect
ribavirin
kitten
name
thrombocytopenia
suppress
bone
marrow
erythroid
myeloid
precursor
povey
weiss
et
al
may
increas
sever
clinic
diseas
induc
fipv
kitten
present
studi
aggrav
clinicopatholog
find
fip
includ
thrombocytopenia
lymphopenia
anaemia
weiss
scott
weiss
although
complet
blood
platelet
count
carri
kitten
studi
find
sever
dissemin
haemorrhag
lesion
kitten
treat
ribavirin
compar
untreat
kitten
strongli
suggest
patholog
effect
induc
fipv
toxic
effect
induc
ribavirin
addit
similarli
ribavirin
much
higher
dosag
mg
kg
bodyweight
given
three
time
daili
per
os
enhanc
sever
diseas
lesion
includ
sever
haemorrhag
clinicopatholog
find
kitten
infect
felin
caliciviru
povey
ribavirin
alon
seem
toxic
use
dosag
like
therapeut
author
attempt
deliv
smaller
dose
drug
specif
tissu
cell
infect
viru
use
ribavirinencapsul
liposom
carriermedi
antivir
therapi
rational
effect
target
liposom
contain
ribavirin
target
cell
fipv
name
mononuclear
phagocyt
liver
lung
spleen
bone
marrow
lymph
node
ward
weiss
scott
b
weiss
would
result
precis
deliveri
antivir
dosag
ribavirin
cell
thu
minimis
distribut
tissu
hope
therapeut
dosag
would
effect
lower
therebi
reduc
toxic
previou
studi
indic
liposom
taken
macrophag
vitro
vivo
bonventr
gregoriadi
alv
macewen
liposom
administ
intraven
concentr
organ
sinusoid
capillari
contain
reticuloendotheli
cell
liver
spleen
bone
marrow
ladigina
vladimirski
popescu
et
al
liposom
encapsul
antimicrobi
drug
dramat
improv
therapeut
efficaci
variou
diseas
particularli
associ
dissemin
intracellular
pathogen
alv
kend
et
al
ladigina
v
adimirski
popescu
et
al
may
reduc
bone
marrow
toxic
antivir
agent
deoxythymidin
azt
phillip
et
al
trial
challeng
dose
fipv
concentraton
ribavirin
administ
kitten
lower
rational
lower
challeng
dose
fipv
maximis
chanc
posit
treatment
effect
either
free
liposom
incorpor
ribavirin
would
observ
kitten
would
overchalleng
viru
gener
recognis
antivir
often
fail
high
inocula
challeng
viru
concentr
ribavirin
lower
minimis
toxic
also
compar
effect
target
low
dose
drug
liposom
effect
equival
dose
free
drug
unfortun
fipvinfect
kitten
treat
liposomeencapsul
ribavirin
protect
induc
fip
kitten
given
empti
liposom
challeng
fipv
actual
increas
mortal
rate
compar
untreat
kitten
given
liposom
ribavirin
reason
decreas
surviv
kitten
given
empti
liposom
unclear
liposomemedi
toxic
perhap
enhanc
fipv
replic
oi
immunopatholog
effect
secondari
releas
cytokin
liposomeactiv
macrophag
may
occur
curious
kitten
given
equival
volum
liposom
ribavirin
better
surviv
rate
kitten
given
empti
liposom
suggest
antivir
effect
attribut
ribavirin
cat
may
counterbalanc
deleteri
effect
liposom
fact
kitten
challeng
expos
fipv
given
empti
liposom
notabl
gross
microscop
chang
tissu
includ
bone
marrow
argu
profound
toxic
effect
liposom
haematolog
biochem
chang
howev
quantifi
kitten
anoth
explan
lack
efficaci
observ
liposomeencapsul
ribavirin
could
liposom
distribut
effect
site
viral
replic
amount
ribavirin
incorpor
liposom
suboptim
dosag
ribavirin
use
load
liposom
cox
l
martinez
mg
kg
bodyweight
per
cent
incorpor
discern
toxic
dosag
also
therapeut
moder
higher
dosag
exampl
mg
kg
bodyweight
appar
toxic
exacerb
clinic
diseas
still
unclear
free
ribavirin
effect
liposomeincorpor
drug
equival
concentr
unless
liposomemedi
toxic
modul
macrophag
cell
somehow
affect
viral
process
antivir
immun
appar
liposom
unabl
target
effect
suffici
antivir
dose
ribavirin
critic
cell
popul
thu
fail
prevent
treat
diseas
manifest
fip
speci
differ
drug
toler
therapeut
index
ribavirin
fipv
cat
compar
mammal
may
contribut
rel
lack
efficaci
free
liposomeencapsul
ribavirintr
anim
studi
kend
et
al
practic
therapeut
window
observ
dosag
ribavirin
use
studi
seem
narrow
clinic
use
ribavirin
consid
primari
antivir
treatment
fip
cat
previou
vitro
studi
ribavirin
indic
even
near
toxic
level
total
inhibitori
fipv
weiss
oostromram
consid
fip
essenti
immunemedi
diseas
initi
induc
rapid
viru
replic
macrophag
rather
classic
type
viral
diseas
associ
viral
cytopath
conceiv
even
small
amount
viru
persist
vivo
ribavirin
treatment
suffici
elicit
immunopatholog
respons
thu
caus
progress
diseas
author
intent
use
antivir
drug
like
ribavirin
primari
treatment
fip
cat
acut
infect
model
suppress
initi
viral
replic
immunopatholog
respons
induc
intent
inhibit
direct
viral
cytopath
effect
immunopatholog
respons
none
less
occur
hope
suppress
circul
viral
load
use
antivir
drug
would
larg
inhibit
direct
stimulu
antibodi
product
therebi
diminish
gener
pathogen
immun
complex
accordingli
rel
amount
complementmedi
inflamm
necrosi
vascul
would
reduc
therebi
allow
host
recov
sever
immunolog
mediat
inflammatori
reaction
catabol
effect
characteris
diseas
appar
amount
antivir
activ
induc
ribavirin
cat
studi
ineffect
modul
immunopatholog
respons
therapeut
arguabl
cat
clinic
fip
present
later
stage
diseas
treatment
may
attempt
cat
acut
experiment
studi
conceiv
rel
much
less
viral
replic
viraemia
perhap
differ
degre
type
immunopatholog
injuri
induc
cat
natur
diseas
compar
kitten
experiment
induc
diseas
acut
infect
model
howev
still
relev
studi
natur
fip
notwithstand
observ
fipv
difficult
isol
clinic
specimen
natur
diseas
particularli
noneffus
case
fip
possibl
viru
markedli
cellassoci
complex
strongli
antibodi
perhap
degrad
proteas
enzym
releas
intens
inflammatori
reaction
possibl
least
small
amount
viru
continu
replic
circul
vivo
clinic
diseas
induc
immunopatholog
lesion
via
immun
complex
mechan
failur
antivir
therapi
amelior
immunopatholog
diseas
suppress
viral
product
experiment
diseas
suggest
approach
alon
would
probabl
ineffect
natur
diseas
immunolog
problem
undoubtedli
advanc
find
indic
concentr
ribavirin
suffici
toler
vivo
effect
treat
cat
infect
fipv
protect
virusinduc
mortal
incorpor
ribavirin
liposom
target
less
toxic
concentr
drug
specif
macrophag
variou
infect
tissu
also
unsuccess
prevent
fatal
fip
ribavirin
shown
induc
synergist
antivir
effect
fipv
combin
agent
human
interferon
z
vitro
weiss
oostromram
improv
clinic
respons
induc
low
dosag
ribavirin
cat
studi
addit
clinic
studi
low
dose
ribavirin
combin
interferon
fipvinfect
cat
may
use
consid
also
host
resist
fipv
allegedli
relat
strong
cellular
immun
respons
black
weiss
effect
therapi
infecti
periton
fip
suggest
previous
may
ultim
depend
upon
use
multipl
drug
use
combin
antivir
immunomodul
antiinflammatori
agent
weiss
barlough
scott
